<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253824</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-01-4</org_study_id>
    <nct_id>NCT01253824</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers</brief_title>
  <official_title>Pharmacodynamics of NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol) and IKH-01( 1mg Norethisterone and 0.035mg Ethinyl Estradiol); Effect of NPC-01 and IKH-01 on Serum Concentrations of Estradiol, Progesterone, FSH and LH.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the serum levels of estradiol, progesterone, FSH and
      LH in NPC-01 or IKH-01 one treatment cycle with those in before and after administration
      cycle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</measure>
    <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
    <description>Estradiol was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</measure>
    <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
    <description>Progesterone was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</measure>
    <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
    <description>FSH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</measure>
    <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
    <description>LH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NPC-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg norethisterone and 0.02mg ethinyl estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IKH-01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1mg norethisterone and 0.35mg ethinyl estradiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-01</intervention_name>
    <description>NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
    <arm_group_label>NPC-01</arm_group_label>
    <other_name>norethisterone and ethinyl estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IKH-01</intervention_name>
    <description>IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
    <arm_group_label>IKH-01</arm_group_label>
    <other_name>norethisterone and ethinyl estradiol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female aged between 20 to 35 years

          -  BMI:18.0-26.0

        Exclusion Criteria:

          -  Females who are pregnant

          -  Drug use affecting sex hormone secretion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takefumi Matuo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hyogo Prefectural AWAJI Hospital</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <results_first_submitted>April 10, 2014</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NPC-01</keyword>
  <keyword>IKH-01</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Norethisterone</keyword>
  <keyword>Ethinyl Estradiol</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Progesterone</keyword>
  <keyword>FSH</keyword>
  <keyword>LH</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Mestranol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifty one subjects were screened for this study after acquiring an informed consent.
18 subjects of those participated in pre-medication menstrual cycle phase to confirm baseline of estradiol, progesterone, FSH and LH.
4 subjects withdrew IC during this phase, therefore, 14 subjects were registered and allocated study drugs.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NPC-01</title>
          <description>1mg norethisterone and 0.02mg ethinyl estradiol
NPC-01: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
        </group>
        <group group_id="P2">
          <title>IKH-01</title>
          <description>1mg norethisterone and 0.35mg ethinyl estradiol
IKH-01: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects were included for safety and pharmacodynamics analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>NPC-01</title>
          <description>1mg norethisterone and 0.02mg ethinyl estradiol
NPC-01: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
        </group>
        <group group_id="B2">
          <title>IKH-01</title>
          <description>1mg norethisterone and 0.35mg ethinyl estradiol
IKH-01: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="2.3"/>
                    <measurement group_id="B2" value="26.1" spread="4.4"/>
                    <measurement group_id="B3" value="26.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.14" spread="4.23"/>
                    <measurement group_id="B2" value="51.86" spread="6.03"/>
                    <measurement group_id="B3" value="51.5" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
        <description>Estradiol was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
        <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NPC-01</title>
            <description>1mg norethisterone and 0.02mg ethinyl estradiol
NPC-01: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
          </group>
          <group group_id="O2">
            <title>IKH-01</title>
            <description>1mg norethisterone and 0.35mg ethinyl estradiol
IKH-01: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
          <description>Estradiol was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
          <units>pg嚚卡ay/mL,</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Difference of estradiol AUC (BL-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1654.7" spread="1652.6"/>
                    <measurement group_id="O2" value="2478.0" spread="793.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of estradiol AUC(FU-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1872.6" spread="1819.2"/>
                    <measurement group_id="O2" value="2434.9" spread="1151.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
        <description>FSH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
        <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NPC-01</title>
            <description>1mg norethisterone and 0.02mg ethinyl estradiol
NPC-01: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
          </group>
          <group group_id="O2">
            <title>IKH-01</title>
            <description>1mg norethisterone and 0.35mg ethinyl estradiol
IKH-01: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
          <description>FSH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
          <units>mIU嚚卡ay/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Differnce of FSH (BL-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.609" spread="20.879"/>
                    <measurement group_id="O2" value="-4.380" spread="18.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of FSH(FP-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.404" spread="41.309"/>
                    <measurement group_id="O2" value="0.538" spread="30.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
        <description>Progesterone was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
        <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NPC-01</title>
            <description>1mg norethisterone and 0.02mg ethinyl estradiol
NPC-01: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
          </group>
          <group group_id="O2">
            <title>IKH-01</title>
            <description>1mg norethisterone and 0.35mg ethinyl estradiol
IKH-01: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
          <description>Progesterone was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
          <units>ng嚚卡ay/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Difference of progesterone(BL-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.171" spread="25.769"/>
                    <measurement group_id="O2" value="93.148" spread="45.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of progesterone(FU-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.711" spread="47.882"/>
                    <measurement group_id="O2" value="59.344" spread="49.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
        <description>LH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
        <time_frame>Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NPC-01</title>
            <description>1mg norethisterone and 0.02mg ethinyl estradiol
NPC-01: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
          </group>
          <group group_id="O2">
            <title>IKH-01</title>
            <description>1mg norethisterone and 0.35mg ethinyl estradiol
IKH-01: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))</title>
          <description>LH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data</description>
          <units>mIU嚚卡ay/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Difference of LH(BL-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.874" spread="41.200"/>
                    <measurement group_id="O2" value="57.124" spread="50.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of LH(FU-SDA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.571" spread="89.546"/>
                    <measurement group_id="O2" value="59.837" spread="25.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NPC-01</title>
          <description>1mg norethisterone and 0.02mg ethinyl estradiol
NPC-01: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol</description>
        </group>
        <group group_id="E2">
          <title>IKH-01</title>
          <description>1mg norethisterone and 0.35mg ethinyl estradiol
IKH-01: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA-J 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Plasminogen increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oligomenorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Department director of clinical development department 1</name_or_title>
      <organization>Nobelpharama</organization>
      <phone>+81-23-5651-1177</phone>
      <email>murakami@nobelpharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

